BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Earnings Results, Misses Expectations By $0.06 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06), Zacks reports. The company had revenue of $131.50 million during the quarter, compared to analyst estimates of $130.05 million. BioCryst Pharmaceuticals’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.28 earnings per share.

BioCryst Pharmaceuticals Trading Down 10.0 %

Shares of BCRX opened at $8.29 on Tuesday. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $9.50. The stock has a fifty day moving average of $8.03 and a 200-day moving average of $7.84.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on BCRX shares. Barclays increased their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Evercore ISI raised their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Needham & Company LLC raised their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.50.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.